We can help you get approved medicine that isn't approved or available in your home country.. To learn more, fill out the form below.
Diffuse Large B-Cell Lymphoma @ Indicated in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of >2
Relapsed or refractory @ Indicated in combination with bendamustine and a rituximab product for treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after ≥2 prior therapies
The information provided herein is not medical advice and is not intend to replace medical advice offered by a health care provider. Please consult your health care provider for advice.
Trade Partners
Franchise
Download PDF
+91-9953494942